Jie Liu
Visiting Scholar
Research interest
Molecular Imaging & Cancer Theranostics
Work Experience
2021.07-present Oncologist, Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China
2023.03-present Postdoctoral Fellow in Oncology, Medical Integration and Practice Center, Shandong University, Jinan, China
Education Background
M.D., Oncology, Shandong First Medical University, 2021
B.Med., Medicine, Qingdao University, 2015
E-mail: linchuangliujie@163.com
Publication:
Liu T, Xu S, Cheng K, Pei J, Wang S, Li C, Li W, Yu Z*, Yu J*, Liu J* (Co-Corresponding Author). Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study. Eur J Nucl Med Mol Imaging. 2024 Aug 12.
Wang B, Pei J, Xu S, Liu J*(Co-Corresponding Author), Yu J*. A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle. J Exp Clin Cancer Res. 2024 Mar 8;43(1):74.
Wang DX, Long JY, Li RZ, Zhang DL, Liu H, Liu J, Tian JC, Li H, Liu J*(Co-Corresponding Author), Zhao HT*, Li T*. Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments. Mol Cancer. 2024 Jan 15;23(1):15.
J, Cheng K, Liu T, Gao M, Wang S, Xu S, Guo Y, Ma L, Li W, Wang B, Yu J, Liu J*(Corresponding Author). Early, non-invasive detection of radiation-induced lung injury using PET/CT by targeting CXCR4. Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1109-1120
Wang B, Pei J, Xu S, Liu J*(Co-Corresponding Author), Yu J*. System analysis based on glutamine catabolic-related enzymes identifies GPT2 as a novel immunotherapy target for lung adenocarcinoma. Comput Biol Med. 2023 Oct;165:107415.
Wang B, Pei J, Xu S, Liu J*(Co-Corresponding Author), Yu J*. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023 Sep 6;14:1246682.
Wang B, Luo Y, Liu T, Xu S, Pei J, Liu J*(Co-Corresponding Author), Yu J*. Assessment of bidirectional relationships between hypothyroidism and endometrial cancer: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2024 May 16;15:1308208.
Wang B, Zou B, Xu S, Zhao C, Pei J, Wang S, Zhao K, Yu J*, Liu J*(Co-Corresponding Author). Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC. Front Oncol. 2023 Jan 20;13:1083417.
Wang B, Pei J, Wang S, Cheng K, Yu J*, Liu J*(Co-Corresponding Author). Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis. Crit Rev Oncol Hematol. 2022 Sep;177:103771.
Wu L, Liu J, Wang S, Bai M, Wu M, Gao Z, Li J, Yu J*, Liu J*(Co-Corresponding Author), Meng X*. Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer. Front Endocrinol (Lausanne). 2022 Jun 30;13:913631.
Wu M#, Liu J#(Co-First Author), Wu S, Liu J, Wu H, Yu J, Meng X. Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer. Front Immunol. 2021 Dec 14;12:803247.
Shang S#, Liu J#(Co-First Author), Verma V, Wu M, Welsh J, Yu J, Chen D. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun (Lond). 2021 Nov;41(11):1086-1099.
Liu J#, Wu L, Liu Z, Seery S, Li J, Gao Z, Yu J, Meng X. 18F-RGD PET/CT and Systemic Inflammatory Biomarkers Predict Outcomes of Patients With Advanced NSCLC Receiving Combined Antiangiogenic Treatment. Front Oncol. 2021 Jun 4;11:671912.
Liu J#, Li C, Seery S, Yu J, Meng X. Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis. Oncoimmunology. 2020 Apr 7;9(1):1746112.
Research Grant:
National Natural Science Foundation of China, Mechanistic study of recombinant TNFα targeting PDGFRβ to improve the immune-suppressive microenvironment of non-small cell lung cancer and enhance immunotherapy. 01/2023-12/2025, host
China Postdoctoral Science Foundation, Molecular imaging-guided individualized radiotherapy based on CXCR4 and mechanistic study in small cell lung cancer.11/2023-11/2025, host
Natural Science Foundation of Shandong: Mechanistic study of the recombinant Z-TNFα targeting tumor cells to overcome immune therapy resistance by improving the tumor immune microenvironment. 01/2023-12/2025, host
Taishan Scholars Program, 06/2023-06-2026, host
Presentation:
American Society for Radiation Oncology(ASTRO)'s 65th Annual Meeting:Early and noninvasive PET imaging of radiation-induced lung injury by targeting CXCR4,
SNMMI 2023 Annual Meeting:Early and noninvasive PET imaging of radiation-induced lung injury by targeting CXCR4 (#66), has been accepted for presentation
EANM’2024 Annual Congress: Molecular imaging of acute radiation-induced esophagitis using PET/CT by targeting CXCR4
CSNM2024’ Annual Congress and Highlight:CXCR4 expression in solid tumors and hematological malignancies by 18F-AlF-NOTA-QHY-04 PET imaging
CSNM2024’ Annual Congress and Highlight:Non-Invasive Identification of Breast Cancer Molecular Subtypes Using PET/CT by Targeting Fibroblast Activation Protein